The frequency of ERBB2 mutations were 10% in cervix carcinomas (n = 2/19), 9% endometrial carcinomas (n = 1/11), 3% in NSCLC (n = 3/101), 4.5% in urothelial carcinomas (n = 2/44), 4.8% in biliary tract carcinomas (n = 2/42), 3.1% in oesogastric carcinomas (n = 1/32), 1.5% in colorectal carcinomas (n = 1/66), 0.7% in breast cancers (n = 1/134). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.